Cosmos Health (NASDAQ:COSM) CEO Grigorios Siokas Buys 349,825 Shares

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 349,825 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was purchased at an average cost of $0.20 per share, for a total transaction of $69,965.00. Following the completion of the transaction, the chief executive officer owned 14,597,917 shares in the company, valued at approximately $2,919,583.40. The trade was a 2.46% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, July 29th, Grigorios Siokas acquired 766,284 shares of Cosmos Health stock. The stock was purchased at an average price of $0.18 per share, for a total transaction of $137,931.12.
• On Thursday, June 11th, Grigorios Siokas acquired 218,447 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.21 per share, with a total value of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas bought 701,447 shares of Cosmos Health stock. The shares were purchased at an average price of $0.23 per share, with a total value of $161,332.81.

Cosmos Health Stock Performance

Shares of COSM stock opened at $0.22 on Friday. The company has a market cap of $12.94 million, a P/E ratio of -0.34 and a beta of 4.83. The firm has a fifty day moving average price of $0.23 and a 200 day moving average price of $0.33. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31. Cosmos Health Inc. has a 12 month low of $0.16 and a 12 month high of $1.32.

Cosmos Health (NASDAQ:COSM) last posted its quarterly earnings results on Wednesday, May 20th. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). The company had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.93 million. Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%. Sell-side analysts predict that Cosmos Health Inc. will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC raised its stake in Cosmos Health by 133.1% during the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after acquiring an additional 128,776 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Cosmos Health by 260.5% in the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after acquiring an additional 241,775 shares in the last quarter. Finally, XTX Topco Ltd boosted its stake in Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after acquiring an additional 34,117 shares in the last quarter. 12.61% of the stock is owned by hedge funds and other institutional investors.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.